Biodesix pipeline test identifies patients likely to respond to immune checkpoint inhibitors

Monday July 20, 2020 0 comments Tags: Boulder, Biodesix, Scott Hutton

BOULDER -- Biodesix, Inc. announced publication of research findings on a diagnostic test capable of generating valuable data to help guide the treatment of patients with advanced non-small cell lung cancer (NSCLC).Biodesix_logoUSE 

The paper, entitled “A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors,” concludes that a proteomic based diagnostic test can provide clinically significant information to predict outcomes of immune checkpoint inhibitor therapy and guide treatment choices made by physicians for patients with advanced NSCLC.

“Publication of this data is an important milestone for Biodesix, and the findings from this study are a direct reflection of our identity and purpose,” said Scott Hutton, CEO of Biodesix.

“We are committed to advancing precision medical care to a level that reduces unnecessary treatment and health care costs, and that focuses on identifying and guiding the best treatment plan for every patient.”

In the retrospective study, mass spectrometry-based proteomic analysis was performed on pretreatment sera derived from advanced NSCLC patients who were treated with nivolumab as part of routine clinical care.

The 289 enrolled patients were stratified into three groups after receiving second-line treatment: good (sensitive), intermediate and poor (resistant). Pooled analysis demonstrated significantly better overall survival rates for "sensitive" relative to "resistant" patients treated with nivolumab.

A signature consisting of 274 mass spectrometry features was associated with progression-free survival and overall survival across two validation groups.

The study demonstrated that this serum-derived proteomic signature successfully stratified outcomes in groups of advanced NSCLC patients treated with second line PD-1 checkpoint inhibitors, Biodesix said.

The paper was authored by Mirte Muller, Karlijn Hummelink, Daan P. Hurkmans, Anna-Larissa N. Niemeijer, Kim Monkhorst, Joanna Roder, Carlos Oliveira, Heinrich Roder, Joachim G. Aerts and Egbert F Smit and published online in Clinical Cancer Research on July 6.